Impact of Pemafibrate on coronary plaque characteristics in ACS patients

Impact of Pemafibrate on coronary plaque characteristics in ACS patients - Pemafibrate and coronary plaque characteristics

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000034434

Enrollment

Registered

2018-10-10

Start date

2018-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ACS patients who underwent OCT guided PCI

Interventions

Pemafibrate Standard therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. ACS(STEMI or NSTEMI/Unstable angina) 2. Presence of coronary artery plaque more than 5 mm from the target lesion for PCI 3. TG>150mg/dl 4. Age > 20yo 5. Written informed consent obtained

Exclusion criteria

Exclusion criteria: 1. SVG or in-stent restenosis lesion 2. Previous history of PCI to the target lesion 3. Vessel with diffuse coronary artery stenosis which is scheduled for PCI 4. Cardiogenic shock 5. Allergy to the study drug (Pemafibrate) 6. Severe lever injury or biliary tract obstruction 7. Moderate to severe renal dysfunction(SCr >2.5mg/dl) 8. Presence of bile stone 9. pregnant or lactating woman 10. Use of Cyclosporine or Rifampicin 11. Insulin requiring diabetes\ 12. Those who are considered as unsuitable candidate by investigators

Design outcomes

Primary

Measure	Time frame
Plaque characteristics by OCT	—

Countries

Japan

Contacts

Public ContactTsunenari Soeda

Nara Medical University Cardiovascular Medicine

soedatn@naramed-u.ac.jp0744-22-3051

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026